Emergent BioSolutions Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 329 million compared to USD 385.2 million a year ago. Net loss was USD 32.7 million compared to net income of USD 39.5 million a year ago. Basic loss per share from continuing operations was USD 1.22 compared to basic earnings per share from continuing operations of USD 1.48 a year ago. For the nine months, revenue was USD 1,069.5 million compared to USD 972.4 million a year ago. Net income was USD 41.6 million compared to USD 119.7 million a year ago. Basic earnings per share from continuing operations was USD 1.55 compared to USD 4.51 a year ago.